Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lentiviral Gene Therapy Against Human Immunodeficiency Virus Type 1, Using a Novel Human TRIM21-Cyclophilin A Restriction Factor

21 Aug 2012

Abstract excerpt

TRIM5α (tripartite motif-containing protein-5, isoform α)-cyclophilin A fusion proteins are anti-human immunodeficiency virus (HIV) restriction factors that have evolved in certain nonhuman primates over millions of years and protect against HIV and related viruses. Restriction by TRIM5αCypA is potent and highly resistant to viral escape by mutation and, in combination with a suitable gene delivery platform,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to HIV Research and Treatment
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22909012
DOI: 10.1089/hum.2012.083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lentiviral Gene Therapy Against Human Immunodeficiency Virus Type 1, Using a Novel Human TRIM21-Cyclophilin A Restriction FactorPMID 22909012Read ↗

Cyclophilin A protects HIV-1 from restriction by human TRIM5αSemantic proximity Read ↗

The control of viral infection by tripartite motif proteins and cyclophilin ASemantic proximity Read ↗

Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by Blocking Human TRIM5α Binding to the Viral Core.Semantic proximity Read ↗

Human TRIM5α: Autophagy Connects Cell-Intrinsic HIV-1 Restriction and Innate Immune Sensor FunctioningSemantic proximity Read ↗

Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene.Semantic proximity Read ↗

Proteasome Inhibition Reveals that a Functional Preintegration Complex Intermediate Can Be Generated during Restriction by Diverse TRIM5 ProteinsSemantic proximity Read ↗

Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1.Semantic proximity Read ↗

Gene Therapy Strategies to Exploit TRIM Derived Restriction Factors against HIV-1Semantic proximity Read ↗

TRIM5α Restricts Flavivirus Replication by Targeting the Viral Protease for Proteasomal DegradationSemantic proximity Read ↗

Proteasomal Degradation of TRIM5α during Retrovirus RestrictionSemantic proximity Read ↗

TRIM5 Retroviral Restriction Activity Correlates with the Ability To Induce Innate Immune SignalingSemantic proximity Read ↗

Capsid-binding retrovirus restriction factors: discovery, restriction specificity and implications for the development of novel therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.